A VM 26-based regimen for patients with previously untreated non-Hodgkin lymphoma. Prolonged disease-free survival in patients younger than 60 years of age: A phase II trial of the eastern cooperative oncology group
✍ Scribed by Leo I. Gordon; Janet Andersen; Stephanie Gregory; Joseph Mazza; Paul Chervenick; Richard G. Hahn; Michael J. O'Connell
- Publisher
- John Wiley and Sons
- Year
- 1993
- Tongue
- English
- Weight
- 545 KB
- Volume
- 71
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
Background. The epidophyllotoxin VM 26 has been shown to have single-agent activity in patients with diffuse aggressive lymphoma. In an attempt to determine its activity in combination with other agents known to be effective in lymphoma, a Phase I1 trial of a novel chemotherapy regimen was conducted.
Methods. Forty-two patients with Stages 11, 111, and IV diffuse aggressive lymphoma were treated with teniposide, doxorubicin, prednisone, cyclophosphamide, vincristine, and bleomycin (PATen-CPOB) as part of a Phase I1 trial of the Eastern Cooperative Oncology Group.